I reported previously (22nd Apr) on Israel’s Mapi and its long-lasting Glatiramer Acetate treatment for Multiple Sclerosis patients. Mapi is now building a production plant in Jerusalem for the product, called GA-Depot, which will compete with Copaxone from Israel’s Teva.

https://www.calcalistech.com/ctech/articles/0,7340,L-3758612,00.html